Earnings ·
Reports Q3 revenue of $524.4M, raises 2026 BRINSUPRI guidance to $1.35B-$1.4B
INSMINSMED Inc
Insmed reported third-quarter 2026 total revenues of $524.4 million, a 268% increase from the prior-year period, driven by strong commercial momentum for its two approved therapies. BRINSUPRI (brensocatib) generated $400.1 million in revenue, reflecting 29% sequential growth, while ARIKAYCE (amikacin liposome inhalation suspension) contributed $124.4 million, up 9% year-over-year. The company raised its full-year 2026 revenue guidance for BRINSUPRI to a range of $1.35 billion to $1.4 billion and for ARIKAYCE to $460 million to $470 million. Insmed also announced the launch of BRINSUPRI tablets in Japan and FDA acceptance of a supplemental new drug application for ARIKAYCE to treat Mycobacterium avium complex lung disease. The biopharmaceutical company develops therapies for serious respiratory, immunology, and neurology diseases.